ARTICLE | Clinical News
Fate Therapeutics preclinical data
June 27, 2016 7:00 AM UTC
In pre-hyperglycemic non-obese diabetic mice, a single dose of ToleraCyte significantly delayed the median time to onset of Type I diabetes to >140 days vs. 115 days for untreated controls (p=0.0004)....